S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
NASDAQ:PSNL

Personalis (PSNL) Stock Price, News & Analysis

$1.49
+0.04 (+2.76%)
(As of 03/28/2024 ET)
Today's Range
$1.46
$1.54
50-Day Range
$1.15
$1.75
52-Week Range
$0.89
$3.27
Volume
266,256 shs
Average Volume
403,149 shs
Market Capitalization
$75.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Personalis MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
269.1% Upside
$5.50 Price Target
Short Interest
Healthy
2.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
0.78mentions of Personalis in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$1,702 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.58) to ($1.25) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.67 out of 5 stars

Medical Sector

66th out of 939 stocks

Medical Laboratories Industry

3rd out of 20 stocks

PSNL stock logo

About Personalis Stock (NASDAQ:PSNL)

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

PSNL Stock Price History

PSNL Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
PSNL Apr 2024 2.500 put
PSNL Apr 2024 7.500 call
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Personalis, Inc. (PSNL)
Personalis: Q4 Earnings Insights
What Wall Street expects from Personalis's earnings
Personalis, ClearNote Health Join Hands To Advance Epigenomic Technology
Personalis Expects Q4 Revenue To Grow 18%
See More Headlines
Receive PSNL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Personalis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:PSNL
Fax
N/A
Employees
223
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.50
High Stock Price Target
$7.50
Low Stock Price Target
$3.50
Potential Upside/Downside
+269.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-108,300,000.00
Net Margins
-147.38%
Pretax Margin
-147.27%

Debt

Sales & Book Value

Annual Sales
$73.48 million
Book Value
$2.64 per share

Miscellaneous

Free Float
46,716,000
Market Cap
$75.25 million
Optionable
Optionable
Beta
1.96
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Christopher M. Hall (Age 55)
    President, CEO & Director
    Comp: $506.39k
  • Mr. Aaron L. TachibanaMr. Aaron L. Tachibana (Age 63)
    CFO & COO
    Comp: $569.6k
  • Dr. Richard Chen M.D. (Age 52)
    M.S., Executive VP of R&D and Chief Medical Officer
    Comp: $584.17k
  • Dr. Russ B. Altman M.D.
    Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Euan A. Ashley DPHIL (Age 53)
    FRCP, M.D., Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Michael P. Snyder Ph.D.
    Co-Founder and Member of Clinical & Scientific Advisory Board
  • Mr. Stephen M. Moore J.D. (Age 51)
    VP, General Counsel & Corporate Secretary
  • Mr. Michael J Fitzpatrick
    Vice President of Worldwide Sales
  • Dr. Christian Haudenschild Ph.D.
    Senior Vice President of Genomic Laboratory Operations
  • Mr. Stephane Mouradian Ph.D.
    Senior Vice President of Business Development

PSNL Stock Analysis - Frequently Asked Questions

Should I buy or sell Personalis stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PSNL shares.
View PSNL analyst ratings
or view top-rated stocks.

What is Personalis' stock price target for 2024?

2 equities research analysts have issued 12 month price objectives for Personalis' shares. Their PSNL share price targets range from $3.50 to $7.50. On average, they predict the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 269.1% from the stock's current price.
View analysts price targets for PSNL
or view top-rated stocks among Wall Street analysts.

How have PSNL shares performed in 2024?

Personalis' stock was trading at $2.10 on January 1st, 2024. Since then, PSNL stock has decreased by 29.0% and is now trading at $1.49.
View the best growth stocks for 2024 here
.

When is Personalis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our PSNL earnings forecast
.

How were Personalis' earnings last quarter?

Personalis, Inc. (NASDAQ:PSNL) released its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.07. The business had revenue of $19.68 million for the quarter, compared to the consensus estimate of $19.56 million. Personalis had a negative net margin of 147.38% and a negative trailing twelve-month return on equity of 61.42%.

What ETF holds Personalis' stock?

ARK Genomic Revolution ETF holds 5,920,884 shares of PSNL stock, representing 0.56% of its portfolio.

What guidance has Personalis issued on next quarter's earnings?

Personalis issued an update on its first quarter 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $18.0 million-$19.0 million, compared to the consensus revenue estimate of $19.1 million.

What is John West's approval rating as Personalis' CEO?

17 employees have rated Personalis Chief Executive Officer John West on Glassdoor.com. John West has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Personalis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Enphase Energy (ENPH), Pfizer (PFE), Dynavax Technologies (DVAX), QUALCOMM (QCOM), Advanced Micro Devices (AMD), NIO (NIO), NVIDIA (NVDA), Viking Therapeutics (VKTX), AbbVie (ABBV) and

When did Personalis IPO?

Personalis (PSNL) raised $100 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Oppenheimer was co-manager.

Who are Personalis' major shareholders?

Personalis' stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (13.61%), GSA Capital Partners LLP (0.81%), Bruce & Co. Inc. (0.61%), Bridgeway Capital Management LLC (0.26%), Green Alpha Advisors LLC (0.24%) and Dimensional Fund Advisors LP (0.22%). Insiders that own company stock include Aaron Tachibana, Christopher M Hall, John Stephen West, Lightspeed Venture Partners Se, Richard Chen and Stephen Michael Moore.
View institutional ownership trends
.

How do I buy shares of Personalis?

Shares of PSNL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PSNL) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners